Keyphrases
Parkinson's Disease
100%
Pathway Inhibitors
100%
Indirect Pathway
100%
Adenosine A2A
100%
Cerebral Blood Flow
75%
Dose Finding
50%
Perfusion Magnetic Resonance Imaging
50%
Randomized Double-blind
25%
Placebo-controlled
25%
Clinically Significant
25%
Receptor Antagonist
25%
Levodopa
25%
Clinical Data
25%
Rodent Studies
25%
Adenosine
25%
Parkinson Patients
25%
Magnetic Resonance Imaging Study
25%
Dose Effect
25%
Flow Response
25%
Study Support
25%
Treatment Duration
25%
Basal Ganglia
25%
Cortical Regions
25%
Symptom Severity
25%
Pharmacodynamics
25%
Effective Dose
25%
Pharmaceutical Development
25%
Arterial Spin Labeling
25%
Dose-ranging
25%
Thalamic
25%
Lower End
25%
Deactivation
25%
Pseudo-continuous Arterial Spin Labeling (pCASL)
25%
Regional Effects
25%
Alertness
25%
Adenosine A2A Receptor (A2AR)
25%
Focus of Attention
25%
Blood Flow Imaging
25%
Drugs in Development
25%
Pharmacodynamic Response
25%
Finding Information
25%
Pallidothalamic
25%
Self-reported Sleepiness
25%
Neuroscience
Parkinson's Disease
100%
Adenosine
100%
Perfusion Magnetic Resonance Imaging
66%
Placebo
33%
L-DOPA
33%
Receptor Antagonist
33%
Magnetic Resonance Imaging
33%
Agonist
33%
Basal Ganglia
33%
Somnolence
33%
Arterial Spin Labeling
33%
Crossover Study
33%
Flow Imaging
33%
Pharmacology, Toxicology and Pharmaceutical Science
Parkinson's Disease
100%
Adenosine
100%
Tozadenant
100%
Adenosine A2a Receptor Antagonist
33%
Placebo
16%
Pharmacodynamics
16%
Levodopa
16%
Preclinical Study
16%
Somnolence
16%
Pharmacodynamic Parameter
16%